Discover 729 paid clinical trials in Vancouver, British Columbia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 729
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
for
Pancreatic Ductal Adenocarcinoma,
Location: Vancouver
Sponsor: British Columbia Cancer Agency
Sex: All
Age: 18+
Code: NCT06574620
Recruiting
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
for
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Location: Vancouver, Vancouver WA, Portland OR, Tigard OR,
Sponsor: Genmab
Sex: Female
Age: 18+
Code: NCT07166094
Phase3, Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
for
Castration-Resistant Prostatic Cancer, Metastasis
Location: Vancouver, Seattle WA, San Francisco CA, Los Angeles CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06863272
Phase1, Phase2, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
for
Non-Small-Cell Lung Cancer,
Location: Vancouver, Edmonds WA, Calgary, Sacramento CA,
Sponsor: ArriVent BioPharma, Inc.
Sex: All
Age: 18+
Code: NCT07185997
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
for
Ovarian Neoplasms, Breast Neoplasms
Location: Kelowna, Los Angeles CA, Encinitas CA, Harvey IL,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT04641247
Phase2, Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
for
Tumours, Gynecological
Location: Vancouver, Aurora CO, La Jolla CA, Columbus OH,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT06796907
Phase1, Phase2, Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
for
Lymphoma, Lymphoma, Non Hodgkin
Location: Vancouver, Palo Alto CA, St Louis MO, Grand Rapids MI,
Sponsor: Treeline Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT07082803
Phase1, Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Vancouver, Seattle WA, Vancouver WA, Eugene OR, Calgary,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06943872
Phase3, Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
for
Breast Neoplasms, Triple Negative Breast Neoplasms,
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
for
Relapsed/Refractory Multiple Myeloma
Location: Vancouver, Seattle WA, Edmonton, Salt Lake City UT,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT04973605
Phase1, Phase2, Recruiting
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
for
Breast Cancer, Lung Cancer, Gastrointestinal Cancer,
Location: Vancouver
Sponsor: British Columbia Cancer Agency
Sex: All
Age: 18+
Code: NCT04273061
Phase2, Recruiting
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma